Viridian Therapeutics, Inc\de

Viridian Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of key proposals.

Viridian Therapeutics announced the successful completion of a $250 million convertible notes offering and a $117 million equity offering, bolstering its financial position for R&D and market expansion.

Viridian Therapeutics reported positive topline results from its Phase 3 REVEAL-2 trial for elegrobart in chronic thyroid eye disease, meeting primary endpoints and showing statistically significant improvements.

Viridian Therapeutics reported Q1 2026 financial results, highlighting readiness for the veligrotug launch with a PDUFA date of June 30, 2026, and positive Phase 3 data for subcutaneous elegrobart.

Viridian reported highly significant Phase 3 REVEAL-1 results for subcutaneous elegrobart in active thyroid eye disease, outlined near-term veligrotug PDUFA on June 30, 2026, and reiterated cash runway to profitability.

Viridian Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its Thyroid Eye Disease (TED) pipeline with key regulatory and clinical milestones achieved.

Viridian Therapeutics, Inc. reported a net loss of $104.9 million for the first quarter ended March 31, 2026, with cash, cash equivalents, and marketable securities totaling $762.2 million.

Viridian Therapeutics reports a $70 million license revenue, significant progress in its veligrotug and VRDN-003 TED programs, and expanded FcRn inhibitor pipeline, alongside increased operating losses.

Viridian Therapeutics reports significant clinical progress for its TED and FcRn programs, including positive Phase 3 data for veligrotug and a $70 million upfront payment from a new Japan licensing agreement.

Viridian Therapeutics reports a net loss for Q1 2025 and provides updates on its thyroid eye disease (TED) and FcRn inhibitor programs, anticipating key data readouts and regulatory submissions.

Viridian Therapeutics reports a net loss of $76.7 million for the third quarter of 2024, while highlighting progress in its clinical programs for thyroid eye disease and FcRn inhibitors.

Viridian Therapeutics reports a net loss of $65 million for the second quarter of 2024, while advancing its clinical programs for thyroid eye disease and other autoimmune disorders.

Viridian Therapeutics, Inc. announced a significant revenue participation right sale of up to $300 million and provided updates on its advanced Thyroid Eye Disease (TED) programs, veligrotug and elegrobart, alongside its FcRn and TSHR inhibitor portfolios.

Viridian Therapeutics' 10-K filing highlights positive Phase 3 results for veligrotug in thyroid eye disease (TED) and outlines plans for BLA submission, while also advancing its FcRn inhibitor portfolio.

Viridian Therapeutics' annual 10-K filing details progress in its pipeline, particularly for thyroid eye disease (TED) treatments and FcRn inhibitors, with key Phase 3 data expected in 2024.

Director Jeffrey Robert Ajer acquired stock options for 32,341 shares of Viridian Therapeutics, Inc. common stock.

Jennifer K. Moses, a Director at Viridian Therapeutics, Inc., acquired stock options for 32,341 shares.

Sarah Gheuens, a Director at Viridian Therapeutics, Inc., acquired stock options on July 1, 2026, as detailed in a recent SEC Form 4 filing.

Fairmount Funds Management LLC, along with its associated entities, has reported a significant acquisition of common stock in Viridian Therapeutics, Inc.

Viridian Therapeutics' Chief Legal Officer, Jennifer Tousignant, received new equity grants and exercised existing restricted stock units, increasing her direct common stock ownership.

Viridian Therapeutics' Chief Financial Officer, Seth Harmon, reported new equity grants including stock options and restricted stock units, alongside the vesting and tax-related disposition of common stock.

Viridian Therapeutics has issued its 2026 proxy statement detailing director elections, auditor ratification, and executive compensation advisory votes.

Viridian Therapeutics has scheduled its 2025 Annual Meeting for June 20, 2025, and is seeking stockholder votes on director elections, auditor ratification, executive compensation, an equity incentive plan amendment, and an employee stock purchase plan.

Viridian Therapeutics is asking stockholders to approve an amended equity incentive plan with an increased share pool and a new employee stock purchase plan at the upcoming annual meeting.

Viridian Therapeutics is urging stockholders to approve an increase in shares available under its equity incentive plan to maintain competitiveness in the biotech talent market and support company growth.

Viridian Therapeutics will hold its annual stockholder meeting on June 17, 2024, with proposals including the election of directors, ratification of the auditor, executive compensation approval, and an amendment to the equity incentive plan.

Viridian Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 17, 2024, to vote on key proposals including director elections, auditor ratification, executive compensation, and an amendment to the equity incentive plan.

Fairmount Funds Management LLC and its affiliate have increased their beneficial ownership in Viridian Therapeutics, Inc. to 14.04% following a recent public offering.

Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC increased their beneficial ownership in Viridian Therapeutics, Inc. to 15.14% through a recent public offering.

Paradigm BioCapital Advisors LP and affiliates have reported a 5.1% beneficial ownership stake in Viridian Therapeutics, Inc.

Bellevue Group AG and its subsidiary, Bellevue Asset Management AG, have reported a 6.6% beneficial ownership stake in Viridian Therapeutics, Inc.

Deep Track Capital, LP and David Kroin have filed a Schedule 13G reporting a 5.3% beneficial ownership stake in Viridian Therapeutics, Inc.

The Vanguard Group filed an amended Schedule 13G, indicating a 0% beneficial ownership in Viridian Therapeutics Inc. following an internal realignment.

Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang reported beneficial ownership of 1.54% of Viridian Therapeutics, Inc. common stock.

Deep Track Capital and affiliates have reduced their beneficial ownership in Viridian Therapeutics to 2.65%, falling below the 5% threshold.